StockNews.com initiated coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Free Report) (TSE:AEZ) in a research note issued to investors on Tuesday. The firm issued a sell rating on the biopharmaceutical company’s stock.
Aeterna Zentaris Stock Down 2.9 %
NASDAQ AEZS opened at $4.42 on Tuesday. The stock’s 50-day simple moving average is $7.48 and its two-hundred day simple moving average is $7.70. Aeterna Zentaris has a twelve month low of $3.96 and a twelve month high of $12.80. The company has a market capitalization of $7.91 million, a price-to-earnings ratio of -0.30 and a beta of 1.60.
Aeterna Zentaris (NASDAQ:AEZS – Get Free Report) (TSE:AEZ) last announced its quarterly earnings data on Tuesday, May 14th. The biopharmaceutical company reported ($4.74) earnings per share for the quarter. Aeterna Zentaris had a negative net margin of 760.32% and a negative return on equity of 83.45%.
Aeterna Zentaris Company Profile
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.
Featured Stories
- Five stocks we like better than Aeterna Zentaris
- Industrial Products Stocks Investing
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- 3 Stocks to Consider Buying in October
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- High Flyers: 3 Natural Gas Stocks for March 2022
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.